U.S. Markets open in 1 min.

Gilead Sciences, Inc. (GILD)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
70.65-0.59 (-0.83%)
At close: 4:00PM EDT

70.71 0.06 (0.08%)
Pre-Market: 9:28AM EDT

People also watch
CELGBIIBAMGNBMYREGN
Full screen
Previous Close71.24
Open71.40
Bid70.95 x 200
Ask71.05 x 100
Day's Range70.64 - 71.90
52 Week Range63.76 - 88.85
Volume10,768,678
Avg. Volume8,547,356
Market Cap92.32B
Beta0.97
PE Ratio (TTM)7.47
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.08 (2.92%)
Ex-Dividend Date2017-06-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Healthcare Guru Samuel Isaly Plays Two Key Biotech Stocks: Synergy Pharmaceuticals Inc (SGPY), Gilead Sciences, Inc. (GILD)
    SmarterAnalyst22 hours ago

    Healthcare Guru Samuel Isaly Plays Two Key Biotech Stocks: Synergy Pharmaceuticals Inc (SGPY), Gilead Sciences, Inc. (GILD)

    Sameul Isaly, founder of one of the world’s most well-known healthcare funds, has made two key moves on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Gilead Sciences Inc (NASDAQ:GILD). Isaly is the managing partner of OrbiMed, a global management firm that has assets under management of over $13 billion. Isaly is closely tracked by investors due to his exceptional track record: at the beginning of 2016, Barron’s said he was the only US mutual fund manager to beat the S&P 500 for an incredible 25 straight years.

  • Gilead's (GILD) HCV Drug Application Accepted in the EU
    Zacks23 hours ago

    Gilead's (GILD) HCV Drug Application Accepted in the EU

    Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.

  • 24/7 Wall St.yesterday

    Major Biotech Short Interest Surges

    The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.